Etoposide scheduling in combination chemotherapy for limited disease small cell carcinoma — A prospective study

Phase II study of oral etoposide and intravenous paclitaxel in extensive-stage small cell lung cancer

“…In another phase I study, Lilenbaum et al treated 39 patients with advanced solid tumors (including SCLC) with etoposide (100 mg/(m 2 day)) on days 1-3 of each 21-day cycle and paclitaxel (escalating doses, administered as a 3 h infusion on day 4 of each cycle) with and without filgrastim support (beginning on day 5) [12]. The major toxicity observed was neutropenia.…”

“…In a recent meta-analysis, its inclusion in treatment regimens resulted in a survival benefit [11]. At the inception of this trial, available data suggested that prolonged exposure to etoposide might offer an advantage over shorter durations of treatment [12,13]. A subsequent investigation by one group compared 8 days versus 5 days of intravenous etoposide as a single agent.…”